Expression of ERK1 and ERK2 in prostate cancer


Submitted: 12 May 2015
Accepted: 27 November 2015
Published: 18 December 2015
Abstract Views: 4881
PDF: 981
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • Norelia Torrealba Department of Biomedicine and Biotechnology, University of Alcalá, Madrid, Spain.
  • Benito Fraile Department of Biomedicine and Biotechnology, University of Alcalá, Madrid, Spain.
  • Gabriel Olmedilla Department of Pathology, Príncipe de Asturias Hospital, Alcalá de Henares, Madrid, Spain.
  • Pilar Martínez-Onsurbe Department of Pathology, Príncipe de Asturias Hospital, Alcalá de Henares, Madrid, Spain.
  • Manuel Guil-Cid Department of Urology, Príncipe de Asturias Hospital, Alcalá de Henares, Madrid, Spain.
  • Ricardo Paniagua Department of Biomedicine and Biotechnology, University of Alcalá, Madrid, Spain.
  • Mar Royuela Department of Biomedicine and Biotechnology, University of Alcalá, Madrid, Spain.
Prostate cancer may emerge as result of dysregulated balance between cell proliferation and death rates, increased angiogenesis and chronic. These processes are regulated by numerous signaling proteins, including the mitogen-activated protein kinases (MAPKs). JNK, p38 and extracellular signal-regulated kinase (ERK) are the three major sub-families of MAPKs. The pro-oncogenic effects of ERK isoforms (ERK1 and ERK2) lie in their aberrant activation through phosphorylation by any mutation along the pathway of receptor tyrosine kinase (RTK)-Ras-Raf-MEK-ERK1/2. Once activated, ERKs phosphorylate cytoskeletal proteins, kinases, and transcription factors. Active ERK proteins induce strong proliferative and anti-apoptotic effects. Our group has tested variations in expression, activation and localization of ERKs in human prostate. Differential ERK1/2 expression and phosphorylation status may be linked to the progression of prostate cancer. The major striking observation is that ERKs are expressed in tumors with higher proportion than normal prostate. We believe that this is an important notion because the status (expression, localization, phosphorylation and the ERK1/ERK2 ratio) of ERK in the prostate may be developed into an important prognostic marker that predicts patient responce to the anti-cancer treatment.

Supporting Agencies

“Instituto de Salud Carlos III” (PI13/01801) of Spain.

Torrealba, N., Fraile, B., Olmedilla, G., Martínez-Onsurbe, P., Guil-Cid, M., Paniagua, R., & Royuela, M. (2015). Expression of ERK1 and ERK2 in prostate cancer. MAP Kinase, 4(1). https://doi.org/10.4081/mk.2015.5265

Downloads

Download data is not yet available.

Citations